Leqembi could give Alzheimer’s patients more time, but road to treatment is long

Leqembi could give Alzheimer’s patients more time, but road to treatment is long

Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease.  But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, … Read more

57 million privately insured adults eligible for GLP-1s

57 million privately insured adults eligible for GLP-1s

Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future … Read more

Noom to offer GLP-1 drug through new weight loss program

Noom to offer GLP-1 drug through new weight loss program

Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.  The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, … Read more

Gilead Lenacapavir cut HIV infections by 96% in trial

Gilead Lenacapavir cut HIV infections by 96% in trial

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Nardus Engelbrecht | AP Gilead‘s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase-three trial data on lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for … Read more